--:--:--LOCAL ·--:--UTC
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    Plug stock market data into your AI agent — one command: Get your free API key →
    LoginGet API Key
    Company data coverage · NASDAQ

    GILD — Gilead Sciences

    Data coverage, completeness and provenance for Gilead Sciences in the Stock Market API — Health Care · Drug Manufacturers - General.

    NASDAQ USA S&P 500 NASDAQ 100
    Core-field completeness
    100.0%
    Statement periods
    FY2021–FY2025
    Filings archived
    0
    Price collection time
    2026-11-19 22:37 UTC

    Stored price coverage

    Source date: 2026-11-19T21:00:01. Source: yfinance. Collection time is shown separately and does not establish a trade date.

    Recent stored price bars, without investment interpretation
    DateCloseCurrencySourceAdjustment basis
    2026-11-19166.5300USDyfinanceSplit- and dividend-adjusted close
    2026-11-18168.9800USDyfinanceSplit- and dividend-adjusted close
    2026-11-17170.2600USDyfinanceSplit- and dividend-adjusted close
    2026-11-16167.5800USDyfinanceSplit- and dividend-adjusted close
    2026-11-13168.0800USDyfinanceSplit- and dividend-adjusted close

    GET /api/v1/companies/GILD/prices · Price parameters and adjustment semantics

    No archived filings are currently stored for this listing.

    Dataset availability · Handle missing data

    Profile

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

    Employees: 17,000 · Website: https://www.gilead.com · Profile fields populated: 75%

    Data completeness by statement

    Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/GILD/financials.

    Income statement9/10 fields (90.0%)
    Balance sheet14/14 fields (100.0%)
    Cash flow6/6 fields (100.0%)
    Per-share3/4 fields (75.0%)

    Financial statement coverage (USD)

    Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.

    PeriodPeriod end RevenueNet incomeTotal assetsTotal equity Fields populatedSource
    FY2025 (USD) 2025-12-31 32 sec_edgar
    FY2024 (USD) 2024-12-31 32 sec_edgar
    FY2023 (USD) 2023-12-31 32 sec_edgar
    FY2022 (USD) 2022-12-31 32 sec_edgar
    FY2021 (USD) 2021-12-31 32 sec_edgar

    Get GILD data via the API

    The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.

    Company profile

    Name, sector, industry, HQ, employees, market cap, source-tagged.

    GET /api/v1/companies/GILD

    Financial statements

    Multi-year statements with per-field source tags and completeness.

    GET /api/v1/companies/GILD/financials

    Computed ratios

    P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.

    GET /api/v1/companies/GILD/metrics/summary

    News & announcements

    Dated press releases and announcements with source links.

    GET /api/v1/companies/GILD/news

    Quick start

    Create a free key, then:

    curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/GILD

    Query GILD programmatically

    Free tier — instant API key. Built for AI agents.

    Frequently Asked Questions

    What data does the API provide for GILD?
    Stored coverage for GILD: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/GILD; inspect available source metadata for provenance.
    How complete is GILD's financial data?
    The anchor reporting period (FY2025) has 100.0% of the 17 core statement fields populated. Primary source: sec_edgar.
    What reporting periods are covered for GILD?
    5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/GILD/financials.
    Where does GILD's data come from?
    Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/GILD/financials; missing tags do not establish provenance.